Comparison of toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: A randomized double-blind, the 'nordic' phase III study

British Journal of Cancer

Volumn 76, Issue 2, 1997, Pages 270-277

  Pyrhonen S ^a   Valavaara, R ^b   Modig, H ^c   Pawlicki, M ^d   Pienkowski, T ^e   Gundersen, S ^f   Bauer, J ^g   Westman, G ^h   Lundgren, S ⁱ   Blanco, G ^j   Mella, O ^k   Nilsson, I ^l   Hietanen, T ^m   Hindy, I ⁿ   Vuorinen, J ^o   Hajba, A ^o  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c Umeå Regional Hospital   (Sweden)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e INSTITUTE OF ONCOLOGY   (Poland)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g CHARLES UNIVERSITY   (Czech Republic)

^h ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^j OULU UNIVERSITY HOSPITAL   (Finland)

^k HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^l Dept of Radiotherapy and Oncology   (Sweden)

^m TAMPERE UNIVERSITY HOSPITAL   (Finland)

ⁿ NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^o ORION CORPORATION   (Finland)

more..

Author keywords

Advanced breast cancer; Antioestrogen; Post menopausal women

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CATARACT; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; SWEATING; THROMBOEMBOLISM; TREATMENT FAILURE; VAGINA BLEEDING; VERTIGO; VOMITING;

EID: 2642657654     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.375     Document Type: Article

References (43)

1. Bonomi P, Gale M, von Roenn J, Andersson K, Johnson P, Wolter J and Wolter J (1988) Quantitative estrogen and progesterone receptor levels related to progression free interval in advanced breast cancer patients treated with megesterol acetate or tamoxifen. Sem Oncol 15 (suppl. 1): 26-33
2. De Gregorio MW. Mäenpää JV und Wiehe VJ (1995) Tamoxifen for the prevention of breast cancer. In Important Advances in Oncology, De Vita VT, Hellman S and Rosenberg SA (eds), pp.175-185. Lippincott: Philadelphia
3. Early Breast Cancer Trialists' Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24.000 deaths among 75,000 woman. Lancet 339: 71-85
4. Fisher B, Constantino JP, Redmond CK, Fisher ER, Wickerham DL and Cronin WM (1994) Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86: 527-537
5. Fornander T, Hellström A-C and Moherger B (1993) Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 85: 1850-1855
6. Gerner EW (1989) Ocular toxicity of tamoxifen. Ann Ophthalmol 21: 420-423
7. Hamm JT, Tormey DC, Kohler PC, Haller D, Green M and Shemano I (1991) Phase I study of toremifene in patients with advanced cancer. J Clin Oncol 9: 2036-2041
8. Han Y and Liehr JG (1992) Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res 52: 1360-1363
9. Hard GC, Iatropoulos MJ, Jordan K, Radi L, Kaltenberg OP, Imondi A and Williams G (1993) Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifene in femal Crl: CD (BR) rats. Cancer Res 53: 4534-4541
10. Hayes D, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I and Schoenfelder J (1995) Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566
11. Heier JS, Dragoo RA, Enzenauer RW and Waterhouse WJ (1994) Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 117: 772-775
12. Hietanen T, Baltina D, Johansson R, Numminen S, Hakala T, Helle L and Valavaara R (1990) High dose toremifene (240 mg daily ) is effective as first line hormonal treatment in advanced breast cancer - an ongoing phase II multicenter Finnish Latvian cooperative study. Breast Cancer Res Treat 16 (suppl.): S37-S40
13. Hirsimäki P, Hirsimäki Y, Nieminen L and Pay ne BJ (1993) Tamoxifen induces hepatocellular carcinoma in rat liver: a I -year study with two antiestrogens. Arch Toxicol 67: 49-54
14. Jaiyesimi IA, Buzdar AU, Decker DA and Hortohagyi GN (1995) Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13: 513-529
15. Jönsson P-E, Malmberg M, Bergljung L, Ingvar C, Ericsson M, Ryden S, Nilsson I and Johansson Terje I (1991) Phase II study of high dose toremifene in advanced breast cancer progressing during tamoxifene treatment. Anticancer Res 11: 873-876
16. Kallio S, Kangas L, Blanco G, Johansson R, Karjalainen A, Perilä M, Piippo I, Sundqvist H, Södcrvall M and Toivola R (1986) A new triphenylethylene compound, FC-1157a. II Hormonal effects. Cancer Chemother Pharmacol 17: 103-108
17. Karlsson S, Hirsimäki Y, Märitylä E, Nieminen L, Kangas L, Hirsimäki P, Perry CJ, Mulhern M, Millar P, Manda J and Williams GM (1996) A two-year dietary carcinogenicity study of the antiestrogen toremifene in Sprague-Dawley rats. Drug Chem Toxi 19: 245-266
18. Kangas L (1992a) Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31: 143-146
19. Kangas L (1992b) General pharmacology and applicability of toremifene, a new anticstrogenic antitumour drug. Eur J Surg Oncol 18 (suppl. 1): 23
20. Kangas L, Nieminen A-L, Blanco G, Grönroos M, Kallio S, Karjalainen A, Peril M, Södervall M and Toivola R (1986) A new triphenylethylene compound, FC-1157a. II. Antilumour effects, Cancer Chemother Pharmacol 17: 109-113
21. Kivinen S and Mäenpää J (1990) Effect of toremifene on clinical chemistry. hematology and hormone levels at different doses in healthy postmenopausal volunleers: phase I study. I. Steroid Biochem 36: 217-220
22. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen P and Laatikainen T (1993) Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynccol 81: 660-664
23. Metzler M and Degen GH (1987) Sex hormones and neoplasia: liver tumours in rodents. Arch Toxicol 10 (suppl.): 251-263
24. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
25. Montandon F and Williams GM (1994) Comparison of DNA reactivity of the polyphenylethylene hormonal agents diethylstilbestrol, tamoxifen and toremifene in rat and hamster liver. Arch Toxicol 68: 272-275
26. Pavlidis NA, Petris C, Briassoulis E, Klouvas G, Psilas C. Rempapis J and Petroutsos G (1992) Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity. Cancer 69: 2961 2964
27. Pyrhönen S (1990) Phase III studies of toremifene in metastatic breast cancer. Breast Cancer Res Treat 16 (supph): S41 S46
28. Pyrhönen S, Valavaara R, Heikkinen M, Rissanen P, Blanco G, Nordman E, Holsti LR and Majba A (1990) Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. J Steroid Biochem 36: 227-228
29. Pyrhönen S, Valavaara R, Vunrinen J and Hajba A (1994) High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment. Breast Cancer Res Treat 29: 223-228
30. Rutqvist L-E, Johansson H, Signomklao T, Johansson U, Fornander T and Wilking N (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 87: 645-651
31. Santen RJ, Manni A, Harvey H and Redmond C (1990) Endocrine treatment of breast cancer in women, Endocrine Rer 11: 221-265
32. Styles JA. Davies A, Lim CK, De Matteis F, Stanley LA, White INH, Yan Z-X and Smith LL (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis 15: 5-9
33. Tominaga T, Abe O. Izuo M and Nomura Y (1993) Phase II study of NK 622 (toremiftene citrate) in advanced breast cancer, a multicentral cooperative dose finding study. Gan To Kagaku Ryoho 20: 79-90
34. Valavaara R and Pyrhönen S (1989) Low-dose toremifene in the treatment of estrogen-receplor-positive advanced breast cancer in postmenopausal women. Curr Therap Res 46: 966-973
35. Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E and Nordman E (1988) Toremifene, a new antiestrogenic compound for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785-790
36. Valavaara R, Tuominen J and Johansson R (1990) Predictive value of tumour estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene. Cancer 66: 2264-2269
37. Vancutsem PM, Lazarus P and Williams GM (1994) Frequent and specific mutations of the rat P53 gene in hepatocarcinomas induced by tamoxifen. Cancer Res 54: 3864-3867
38. Vogel CL, Shemano I. Schoenfelder J, Gams RA and Green MR (1993) Multicenter phase II efficacy trial of toremifene in tamoxifen-refaclory patients with advanced breast cancer. J Clin Oncol 11: 345-350
39. Vuorio T, Wärri A, Sandberg M, Alitalo K and Vuorio E(1988) Expression of the c-Ha-ras and neu oncogenes in DMBA-induced, anticstrogen-treated rat mammary tumours. Int J Cancer 42: 774-779
40. Wärri AM, Huovinen RL, Laine AM, Martikainen PM and Härkönen PL (1993) Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418
41. White IN, De Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A and Phillips DH (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344 /n rats. DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13: 2197-2203
42. Williams GM, Iatropoulos M, Cheung R, Rudi L and Wang CX (1993) Diethylstilbestrol liver carcinogenicity and modification of DNA in rats (letter). Cancer 68: 193-198
43. Zito R (1994) Problems in breast cancer prevention and therapy with tamoxifen. J Exp Clin Cancer Res 13: 99-102